AC Immune SA (NASDAQ:ACIU) trading at $4.76 after increase. On Mar, 24 it was announced by Barchart.com. The company has $320.65 million market cap. $28.86 million more could be NASDAQ:ACIU valuation at $5.19 share price.

More recent AC Immune SA (NASDAQ:ACIU) news were brought out by Globenewswire.com, Benzinga.com and Globenewswire.com. The first one has “AC Immune to Report Progress of Early-Stage Pipeline at AD/PDâ„¢ Congress – GlobeNewswire” as a title and was brought out on March 04, 2019. The next is “31 Stocks Moving In Thursday’s Pre-Market Session – Benzinga” on March 21, 2019. And last was brought out on March 21, 2019, called “AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update – GlobeNewswire”.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.The firm is worth $320.65 million. The Company’s SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s , ParkinsonÂ’s, down syndrome, and glaucoma diseases.Last it reported negative earnings. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies.